tetano
Editor, Senior Moderator
Pancreatology
. 2022 Mar 25;S1424-3903(22)00103-X.
doi: 10.1016/j.pan.2022.03.014. Online ahead of print.
Prevalence and prognosis of increased pancreatic enzymes in patients with COVID-19: A systematic review and meta-analysis
Feng Yang[SUP] 1 [/SUP], Yecheng Xu[SUP] 2 [/SUP], Yinlei Dong[SUP] 2 [/SUP], Yuting Huang[SUP] 3 [/SUP], Yunting Fu[SUP] 4 [/SUP], Tian Li[SUP] 5 [/SUP], Chenyu Sun[SUP] 6 [/SUP], Sanjay Pandanaboyana[SUP] 7 [/SUP], John A Windsor[SUP] 8 [/SUP], Deliang Fu[SUP] 9 [/SUP]
Affiliations
Abstract
Introduction: The prevalence of increased pancreatic enzymes (elevated serum amylase and/or lipase) and its relationship to clinical outcomes in patients with coronavirus disease 2019 (COVID-19) infection is not known.
Methods: A systematic review and meta-analysis of relevant studies reporting prevalence and impact of increased pancreatic enzymes (defined as an elevation in amylase and/or lipase levels above the upper limit of normal [ULN] value) in COVID-19 was undertaken.
Results: A total of 36,496 patients from 21 studies were included for this meta-analysis. The overall prevalence and mortality for increased pancreatic enzymes (>ULN) in COVID-19 were 25.4% (95% CI, 15.8%-36.2%) and 34.6% (95% CI, 25.5%-44.4%), respectively. The overall prevalence and mortality for increased pancreatic enzymes (>3 × ULN) were 6.1% (95% CI, 3.6%-9.2%) and 39.2% (95% CI, 18.7%-61.6%), respectively. Patients with increased pancreatic enzymes, including elevated serum lipase or amylase of either type, had worse clinical outcomes, including need for ICU admission, mechanical ventilation and mortality.
Discussion: Increased pancreatic enzymes is frequent and may exacerbate the consequences of COVID-19 infection.
Keywords: Amylase; COVID-19; Lipase; Prevalence; Prognosis.
. 2022 Mar 25;S1424-3903(22)00103-X.
doi: 10.1016/j.pan.2022.03.014. Online ahead of print.
Prevalence and prognosis of increased pancreatic enzymes in patients with COVID-19: A systematic review and meta-analysis
Feng Yang[SUP] 1 [/SUP], Yecheng Xu[SUP] 2 [/SUP], Yinlei Dong[SUP] 2 [/SUP], Yuting Huang[SUP] 3 [/SUP], Yunting Fu[SUP] 4 [/SUP], Tian Li[SUP] 5 [/SUP], Chenyu Sun[SUP] 6 [/SUP], Sanjay Pandanaboyana[SUP] 7 [/SUP], John A Windsor[SUP] 8 [/SUP], Deliang Fu[SUP] 9 [/SUP]
Affiliations
- PMID: 35361531
- PMCID: PMC8949660
- DOI: 10.1016/j.pan.2022.03.014
Abstract
Introduction: The prevalence of increased pancreatic enzymes (elevated serum amylase and/or lipase) and its relationship to clinical outcomes in patients with coronavirus disease 2019 (COVID-19) infection is not known.
Methods: A systematic review and meta-analysis of relevant studies reporting prevalence and impact of increased pancreatic enzymes (defined as an elevation in amylase and/or lipase levels above the upper limit of normal [ULN] value) in COVID-19 was undertaken.
Results: A total of 36,496 patients from 21 studies were included for this meta-analysis. The overall prevalence and mortality for increased pancreatic enzymes (>ULN) in COVID-19 were 25.4% (95% CI, 15.8%-36.2%) and 34.6% (95% CI, 25.5%-44.4%), respectively. The overall prevalence and mortality for increased pancreatic enzymes (>3 × ULN) were 6.1% (95% CI, 3.6%-9.2%) and 39.2% (95% CI, 18.7%-61.6%), respectively. Patients with increased pancreatic enzymes, including elevated serum lipase or amylase of either type, had worse clinical outcomes, including need for ICU admission, mechanical ventilation and mortality.
Discussion: Increased pancreatic enzymes is frequent and may exacerbate the consequences of COVID-19 infection.
Keywords: Amylase; COVID-19; Lipase; Prevalence; Prognosis.